eBook: Antibody–drug conjugate bioanalysis
Antibody-drug conjugates (ADCs) are a relatively new therapeutic modality compared to small molecule medicines. With the increased momentum behind the development of ADCs, there has been a corresponding increase in the bioanalytical needs for this therapeutic class. In this eBook, we will explore the development of the bioanalytical assays needed to support the advancement of ADCs from the candidate selection phase through the regulatory submission process.
CONTENTS INCLUDE:
- INTERVIEW: 60 seconds with David Johnson, Michelle Miller and Amanda Hays
- COMMENTARY: Immunogenicity considerations for antibody–drug conjugates: a focus on neutralizing antibody assays
- PERSPECTIVE: Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics
In association with:
